A First-in-Human, Phase 1a, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Healthy Adult Subjects
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Navenibart (Primary) ; Navenibart (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Astria Therapeutics
- 30 Aug 2024 According to an Astria Therapeutics Media Release, data from this trial will be presented at the upcoming Bradykinin Symposium
- 24 May 2024 According to an Astria Therapeutics media release, the company will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.
- 04 Mar 2024 According to an Astria Therapeutics media release, the final results from the Phase 1a trial were shared at the AAAAI Annual Meeting in Washington D.C.